WINT
Windtree Therapeutics, Inc.
5.23
+
0.13
2.55%
1 x 5.01
1 x 5.64
bid
ask
1 @ 07:58 PM
5.07-0.16 (3.06%)
Bearish
4
Bullish
12
sentiment
5.06
day range
5.51
5.07
52 week range
32.22
Prev Close5.10
Open5.06
Low5.06
High5.51
Volume28.36K
Avg. Volume15.07K
Market Cap2.67M
Inst. Own12.91%
Beta0.59
Short Ratio0.35
Div & Yield0.00 /
EPS-94.32
P/E0.00
1yr Target3.00
50day MA6.55
200day MA14.81
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
(WINT)- Investing.com UK | news.google.com • |
What made Windtree Therapeutics stock tank 20% on Monday? | invezz.com • |
What made Windtree Therapeutics stock tank 20% on Monday? | news.google.com • |
Windtree to Present at the Sidoti Micro Cap Conference on November 16th | globenewswire.com • |
Windtree to Present at the ThinkEquity Conference on October 19th in New York City | globenewswire.com • |
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th | globenewswire.com • |
Profile
...
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor
for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | 0 | N/A | N/A | N/A |
2024-04-16 | 2023-12 | 0 | -13.31 | N/A | N/A |
2023-11-09 | 2023-09 | 0 | -15.47 | N/A | N/A |
2023-08-07 | 2023-06 | 0 | -29.5 | N/A | N/A |
2023-05-15 | 2023-03 | 0 | -85.61 | N/A | N/A |
2023-04-03 | 2022-12 | 0 | -233.99 | N/A | N/A |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-03-03 | CARMAN DIANE | General Counsel | 66.30K | Stock Award(Grant) |
2023-08-22 | CURTIS ERIC | Chief Operating Officer | 15.92K | Stock Award(Grant) |
2023-09-26 | FRASER CRAIG E | Chief Executive Officer | 57.88K | Purchase |
2023-08-22 | GEFFKEN DANIEL E | Director | 2.17K | Stock Award(Grant) |
2022-07-25 | HAMILL JOHN P | Chief Financial Officer | 72.80K | Purchase |
2023-02-21 | HUANG JAMES Z | Director | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Virtu Financial LLC | 42.67K | 53.33K | 0.83% |
2023-06-29 | Acadian Asset Management. LLC | 31.58K | 39.48K | 0.61% |
2023-06-29 | Citadel Advisors Llc | 21.72K | 27.15K | 0.42% |
2023-06-29 | Two Sigma Securities, LLC | 16.87K | 21.09K | 0.33% |
2023-06-29 | Tower Research Capital LLC (TRC) | 7.23K | 9.03K | 0.14% |
2022-12-30 | Game Plan Financial Advisors, LLC | 360.00 | 3.06K | 0.01% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 8.88K | 11.10K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.55K | 3.26K | 0.05% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 381.00 | 487.00 | 0.01% |
Split
...
Split | Date |
---|---|
1 : 17 | 2024-04-22 |
1 : 50 | 2023-02-24 |
1 : 3 | 2020-04-29 |
1 : 20 | 2017-12-22 |
1 : 14 | 2016-01-22 |
0.06667 : 1 | 2010-12-28 |
This topic has been deleted. Only users with topic management privileges can see it.
-
$WINT no words..The combined 2021-2022 compensation for the top 3 executives per the sec filing today is $5,744,662, almost equivalent to the entire market cap of the company now, $7,155,607. Per https://www.sec.gov/ix?doc=/Archives/edgar/data/946486/000143774923011914/wint20221231_10ka.htm#item12
-
I buy more at the dip 🥳
-
I ve 2240 shares on WINT… just waiting the offering
-
Illegal shorts the stock when markets closed !!!
-
I l’ose all money … in at 8.40$
-
Reversal now.. 🥳 see for Ah
-
-
Strong buy 100%
🥳🥳🥳🥳 -
19-25$ today… maybe squeeze after this
-
-
Wow........
-
This thing dead or is it going up anytime soon?
-
No pump and dump hold hold make some money
-
-
(WINT)- Investing.com UK
news.google.com • -
What made Windtree Therapeutics stock tank 20% on Monday?
news.google.com • -
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
globenewswire.com • -
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
investorplace.com • -
3 Penny Stocks To Watch Before Next Week; Time To Buy?
pennystocks.com • -
Why Is Windtree Therapeutics (WINT) Stock Down 58% Today?
investorplace.com • -
Why Is Windtree Therapeutics (WINT) Stock Up 190% Today?
investorplace.com • -
What The Stock Market Did Today & Top Penny Stocks To Watch Now
pennystocks.com • -
Windtree to Present at the Ladenburg Thalmann Healthcare Conference
globenewswire.com • -
Popular Penny Stocks For Your Buy List Today? 3 to Watch
pennystocks.com • -
Why Is Windtree Therapeutics (WINT) Stock Up 50%?
investorplace.com • -
Check These Penny Stocks For Your Watchlist This Week
pennystocks.com • -
Windtree Therapeutics Stock Is Trading Higher: Here's Why
benzinga.com • -
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
globenewswire.com • -
Windtree to Present at Oppenheimer's 32nd Annual Healthcare Conference
globenewswire.com • -
Why Are Windtree Therapeutics Shares Trading Higher Today?
benzinga.com • -
2 Moonshot Biotechs with 10x Potential
investorplace.com • -
Windtree to Present at Access to Giving Virtual Investor Conference
globenewswire.com • -
WINT Stock Price: 36.36% Increase Explanation
pulse2.com • -
Meme Penny Stocks, What Are They, and 3 to Watch Right Now
pennystocks.com • -
Why Windtree Therapeutics Stock Is Moving Today
benzinga.com • -
7 Beaten Down Stocks with Significant Insider Buying
investorplace.com • -
2 Falling Knives to Catch
gurufocus.com •